Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 1999

View Archived Issues

HIV protease-activated Casp3 protein specifically targets infected cells

In vivo function, migration of CTLs in HIV immunotherapy

Orchid and U. of Washington collaborate on genotyping technology

Diagnocure's bladder cancer diagnostic progresses towards approval in U.S.

Discovery of new mouse appetite gene

ADMA, a novel marker for artherosclerosis?

AVI BioPharma: Q4 and year-end 1998 results

GeneMedicine awarded two SBIR grants for gene therapy expression

NeXstar: Q4 and 1998 year-end results

TerraGen Diversity to acquire ChromaXome from Trega Biosciences

Major clinical study confirms efficacy and safety of rivastigmine in AD

Novel bis-acridine antitumor agents discovered by Italian university researchers

James Black Foundation describes series with antagonist or inverse agonist activity at H3 receptors

Corixa announces issue of new U.S. patent covering HER-2/neu protein

Serotonergic agents in development at Lilly for CNS and other disorders

New study supports renewed interest in the study of MGDF

Platelet P2T antagonists patented by Astra, useful as antithrombotics

New triazoles from Sankyo with excellent antifungal activity

Dainippon patents antibacterial pyridonecarboxylic acid derivatives

Levalbuterol effective against exercise-induced bronchospasm at lower doses than albuterol

AWD-12-281: new PDE4 inhibitor with strong antiinflammatory effects, low emetic potential

Rhone-Poulenc and Hoechst opt to speed up the merger process

FDA approves expanded use of Mevacor

Diprivan approved for sedative use in Japanese ICUs

Two insulin-sensitizing thiazolidinediones up for FDA advisory committee review in April

Phase I trial of Progen's PI-88 successfully completed

Three of four PDE4 inhibitors tested in guinea pigs do inhibit allergen-induced bronchospasm

Schering-Plough files for U.K. approval of mometasone furoate for asthma indication

Progenics licenses vitamin C derivative from Sloan-Kettering

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...